Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
Business & Industry
- Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
- Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses within Africa
- U.S. FDA grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 vaccine
- Collaboration between AbbVie, Biogen and Pfizer creates world's largest browsable resource linking rare protein-coding genetic variants to human health and disease
- Tezepelumab granted Priority Review by U.S. FDA
Research & Development
- Antibiotics may help to treat melanoma
- Take your best shot: Which SARS-CoV-2 vaccine should I get, if any?
- Study shows why second dose of COVID-19 vaccine shouldn't be skipped
- Are silver nanoparticles a silver bullet against microbes?
- One shot of the Sputnik V vaccine triggers strong antibody responses
- "Long COVID": More than a quarter of COVID-19 patients still symptomatic after 6 months
- Artificial intelligence could be new blueprint for precision drug discovery
Conferences & Events
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Regulatory Affairs
- FDA approves first oral blood thinning medication for children
- FDA grants accelerated approval for Alzheimer's drug
- FDA approves new drug treatment for chronic weight management, first since 2014
- FDA authorizes additional monoclonal antibody for treatment of COVID-19
- FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic